Status: 09.05.2022 15:23
BioNTech continues to benefit from strong demand for its Corona vaccine. In the first three months of the year alone, the manufacturer from Mainz made a profit of 3.7 billion euros. It is unclear when the omicron vaccine will arrive.
Corona vaccine Comirnaty brings Mainz-based manufacturer BioNTech into further growing profits. In the first quarter of this year alone, the company generated a plus of 3.7 billion euros. This is more than three times what it was a year ago. At the time, the surplus was 1.1 billion euros.
The increase in sales was just as strong. Revenues have more than tripled, from two billion euros to 6.4 billion euros. CFO Jens Holstein justified the increase in sales and profits with the “Omicron effect”. “Following an increase in the volume of orders received in late 2021 due to the emerging Omikron variant, we entered 2022 with strong sales and results,” said Holstein.
Sales decline expected in 2022
For the full year, however, BioNTech executives expect sales to decline as demand for vaccines is likely to slow as corona restrictions ease. The Mainz-based manufacturer assumes vaccine revenues of between 13 and 17 billion euros. To make a comparison: in 2021 BioNTech achieved sales of almost 19 billion euros and a profit of 10.3 billion euros.
BioNTech partner Pfizer also recently confirmed its $ 32 billion sales forecast for the vaccine. BioNTech and the US group have signed supply contracts for approximately 2.4 billion doses of the vaccine for 2022. In 2021, approximately 2.6 billion cans were delivered.
When will the Omicron vaccine arrive?
A vaccine adapted against the highly contagious variant of the Micron could give businesses a new boost. However, it is still unclear when the vaccine will be on the market. BioNTech initially assumed that the Omicron vaccine could be available in the spring. The Mainz-based company announced the first results of the clinical trial that began in January to mid-April. Now these should only arrive in the next few weeks. Regulation is the cause of the delay, BioNTech chief Ugur Sahin recently said.
The European Medicines Agency EMA has asked pharmaceutical companies not only to develop a so-called monovalent vaccine, which is a vaccine specifically designed for Omicron, but also versions that include a combination of variants. The study has since expanded to include several new cohorts, including one that also studies a larger omcron vaccine covering the original Wuhan variant.
A Covid vaccine for children under the age of five has not yet been approved. BioNTech expects data from the clinical study in the coming weeks. SPD Federal Health Minister Karl Lauterbach does not plan vaccines adapted to the new variants until autumn. BioNTech, on the other hand, offered to make a new adapted vaccine available in the early summer.
US manufacturer Moderna is also working on a vaccine that is said to be equally effective against omicron and other variants. The US company is developing a so-called “pan vaccine”, as are the German company CureVac and the British partner GSK.
Experts predict a large number of new crown variants that may appear in the coming months. Doctors recently warned at the German Congress of Internal Medicine that numerous sub-variants of omicron already exist.